Fig. 7From: CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axisCircVAPA facilitates SCLC proliferation through regulating IGF1R in vivo and in vitro. a Western blot analysis of the effect of SCLC stable cell line with circVAPA knockdown or the control with or without IGF1R inhibitor (drug BMS-536924) on AKT and its downstream protein expression. b-c Cell viability (b) and colony formation (c) assays of the SCLC stable cell line with circVAPA knockdown or the control with or without IGF1R inhibitor (drug BMS-536924). d-f Therapeutic efficacy of circVAPA depletion and IGF1R inhibitor (drug BMS-536924) as single-agents or in combination in vivo (n = 5 for each group). Tumor weights (d), tumor volume curves (e), and tumor photos (f) of xenograft tumors treated with circVAPA depletion and IGF1R inhibitor alone or in combination. g Immunohistochemistry analysis of IGF1R and p-AKT in tumors. Scale bar, 50 μm. h Model patterns of circVAPA/miR-377-3p & miR-494-3p/IGF1R/AKT axis. Vehicle, negative control cells for silencing circVAPA; sh-circVAPA, stable cell line with lentivirus shRNA to knockdown circVAPA; IGF1Ri, the addition of IGF1R inhibitor (drug BMS-536924). (All data are presented as the mean ± SD; ns, no significance; *P < 0.05; **P < 0.01; ***P < 0.001 by two-tailed Student’s t-test). Three independent assays were performed in the above assaysBack to article page